Braga Carlos Galvão, Cid-Alvarez Ana Belén, Diéguez Alfredo Redondo, Alvarez Belén Alvarez, Otero Diego López, Sánchez Raymundo Ocaranza, Pena Xoan Sanmartin, Salvado Violeta González, Trillo-Nouche Ramiro, González-Juanatey José R
Cardiology Department, University Clinical Hospital of Santiago de Compostela, Santiago de Compostela, Spain; Cardiology Department, Hospital de Braga, Braga, Portugal.
Cardiology Department, University Clinical Hospital of Santiago de Compostela, Santiago de Compostela, Spain.
Int J Cardiol. 2017 Sep 15;243:21-26. doi: 10.1016/j.ijcard.2017.04.054. Epub 2017 Apr 20.
The residual SYNTAX score (rSS) was designed and validated to quantify the burden of residual coronary artery disease after percutaneous coronary intervention (PCI). The aim of this study was to assess the prognostic impact of rSS in patients with ST-segment elevation myocardial infarction (STEMI) and multivessel disease undergoing primary-PCI.
This retrospective cohort study included 1499 consecutive patients with STEMI who underwent primary-PCI between January 2008 and December 2015. After exclusion criteria, the multivessel disease cohort (n=535) was divided into three groups, according to rSS: complete revascularization (rSS=0; n=198), reasonable incomplete revascularization (0<rSS<8; n=238) and incomplete revascularization (rSS≥8; n=99).
In-hospital mortality was significantly lower in patients with complete and reasonable incomplete revascularization, when compared to those with incomplete revascularization (1.5% vs. 1.7% vs. 9.0%, p<0.001). During follow-up (median 2.4years), rSS was positively correlated with MACE (25.3% for rSS=0 vs. 31.1% for 0<rSS<8 vs. 47.0% for rSS≥8, p=0.001) and all-cause mortality (5.1% vs. 10.5% vs. 19.2%, p=0.001). The rSS was also an independent predictor of MACE (when compared with complete revascularization, odds ratio [OR] was 1.5 for reasonable incomplete and 1.8 for incomplete revascularization) and all-cause mortality during follow-up (OR 2.9 for reasonable incomplete and 3.9 for incomplete revascularization), adding prognostic value over control variables and GRACE.
In a real-world cohort of patients with STEMI and multivessel disease who underwent PCI, the rSS added important prognostic information over control variables and GRACE, being an independent predictor of MACE and all-cause mortality during follow-up.
残余SYNTAX评分(rSS)旨在量化经皮冠状动脉介入治疗(PCI)后残余冠状动脉疾病的负担,并已得到验证。本研究的目的是评估rSS对ST段抬高型心肌梗死(STEMI)和多支血管病变且接受直接PCI治疗患者的预后影响。
这项回顾性队列研究纳入了2008年1月至2015年12月期间连续1499例接受直接PCI治疗的STEMI患者。经过排除标准筛选后,多支血管病变队列(n = 535)根据rSS分为三组:完全血运重建(rSS = 0;n = 198)、合理不完全血运重建(0 < rSS < 8;n = 238)和不完全血运重建(rSS≥8;n = 99)。
与不完全血运重建的患者相比,完全血运重建和合理不完全血运重建患者的院内死亡率显著降低(1.5%对1.7%对9.0%,p < 0.001)。在随访期间(中位时间2.4年),rSS与主要不良心血管事件(MACE)呈正相关(rSS = 0时为25.3%,0 < rSS < 8时为31.1%,rSS≥8时为47.0%,p = 0.001)以及全因死亡率(5.1%对10.5%对19.2%,p = 0.001)。rSS也是随访期间MACE(与完全血运重建相比,合理不完全血运重建的比值比[OR]为1.5,不完全血运重建为1.8)和全因死亡率(合理不完全血运重建为2.9,不完全血运重建为3.9)的独立预测因子,在控制变量和GRACE评分基础上增加了预后价值。
在接受PCI治疗的STEMI和多支血管病变的真实世界队列患者中,rSS在控制变量和GRACE评分基础上增加了重要的预后信息,是随访期间MACE和全因死亡率的独立预测因子。